Generic Name:
Avelumab
Project Status:
Complete
Therapeutic Area:
Urothelial Carcinoma (UC)
Manufacturer:
EMD Serono - Pfizer Alliance
Brand Name:
Bavencio
Project Line:
Reimbursement Review
Project Number:
PC0225-000
NOC Date:
Details
Strength:
20 mg/mL
Tumour Type:
Genitourinary
Indications:
Urothelial Carcinoma (UC)
Funding Request:
Bavencio is indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.
Review Status:
Notification to Implement Issued
Pre Noc Submission:
Yes
Sponsor:
EMD Serono - Pfizer Alliance
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
pERC Meeting:
Final Recommendation Issued: